ATE478076T1 - Azaxanthonen zur behandlung von tumoren - Google Patents

Azaxanthonen zur behandlung von tumoren

Info

Publication number
ATE478076T1
ATE478076T1 AT06851384T AT06851384T ATE478076T1 AT E478076 T1 ATE478076 T1 AT E478076T1 AT 06851384 T AT06851384 T AT 06851384T AT 06851384 T AT06851384 T AT 06851384T AT E478076 T1 ATE478076 T1 AT E478076T1
Authority
AT
Austria
Prior art keywords
tumors
azaxanthones
treatment
mesenchymel
retarding
Prior art date
Application number
AT06851384T
Other languages
English (en)
Inventor
Grzegorz Pietrzynski
Valery Alakhov
Alexandre Semov
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ATE478076T1 publication Critical patent/ATE478076T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AT06851384T 2005-12-13 2006-12-12 Azaxanthonen zur behandlung von tumoren ATE478076T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/301,930 US7772255B2 (en) 2005-12-13 2005-12-13 Method of treating tumors with azaxanthones
PCT/IB2006/004291 WO2008020269A2 (en) 2005-12-13 2006-12-12 A method of treating tumors with azaxanthones

Publications (1)

Publication Number Publication Date
ATE478076T1 true ATE478076T1 (de) 2010-09-15

Family

ID=38140264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06851384T ATE478076T1 (de) 2005-12-13 2006-12-12 Azaxanthonen zur behandlung von tumoren

Country Status (7)

Country Link
US (2) US7772255B2 (de)
EP (1) EP1968981B1 (de)
JP (1) JP2009519318A (de)
AT (1) ATE478076T1 (de)
CA (1) CA2633112A1 (de)
DE (1) DE602006016333D1 (de)
WO (1) WO2008020269A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089707A1 (en) * 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
CN101899051B (zh) * 2010-05-17 2013-03-20 中国人民解放军第二军医大学 1-氮杂呫吨酮-3-甲酰胺类化合物及制备方法和抗肿瘤用途
WO2012016930A1 (en) 2010-08-05 2012-02-09 Universite De Droit Et Sante De Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
EP2675275B1 (de) * 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Zusammensetzungen und verfahren zur behandlung von adipositas und damit zusammenhängenden erkrankungen
US8946424B2 (en) 2013-05-02 2015-02-03 The Regents Of The University Of Michigan Deuterated amlexanox
WO2017112954A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
EP3407974A4 (de) * 2016-01-29 2019-08-28 The Regents Of The University Of Michigan Amlexanox-analoga
JP2020525434A (ja) * 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
CN109718374B (zh) * 2017-10-27 2022-03-08 中国科学院分子细胞科学卓越创新中心 Irf3抑制剂在制备yap过度激活的癌症的治疗或预防药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53111096A (en) * 1977-03-08 1978-09-28 Takeda Chem Ind Ltd 1-azaxanthone-3-carboxylic acid derivative and its preparation
CA1087188A (en) 1977-03-08 1980-10-07 Hirosada Sugihara 1-azaxanthone-3-carboxylic acids
US4539326A (en) * 1982-08-20 1985-09-03 Takeda Chemical Industries, Ltd. 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents
JP2963496B2 (ja) * 1989-06-26 1999-10-18 第一製薬株式会社 ベンゾピラノピリジン誘導体
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6974806B2 (en) * 2000-07-13 2005-12-13 Takeda Pharmaceutical Company Limited Lipid-rich plaque inhibitors
US20020103219A1 (en) * 2000-10-05 2002-08-01 Jeremy Jacob Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
EP1569942A2 (de) * 2002-12-12 2005-09-07 Pharmacia Corporation Tricyclische aminocyanopyridininhibitoren von mitogenaktivierter proteinkinaseaktivierter proteinkinase-2

Also Published As

Publication number Publication date
HK1116186A1 (en) 2008-12-19
WO2008020269A3 (en) 2008-07-24
EP1968981A4 (de) 2009-04-15
CA2633112A1 (en) 2008-02-21
WO2008020269A2 (en) 2008-02-21
EP1968981B1 (de) 2010-08-18
US20070135473A1 (en) 2007-06-14
DE602006016333D1 (de) 2010-09-30
JP2009519318A (ja) 2009-05-14
US7772255B2 (en) 2010-08-10
EP1968981A2 (de) 2008-09-17
US20090042923A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
DE602006014843D1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
CY1116728T1 (el) Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EP1844077A4 (de) Dr5-antikörper und deren verwendung
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
GEAP202215447A (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
CY1117423T1 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DE602004024037D1 (de) Substituierte heterozyklen
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
EP1694364A4 (de) System zur behandlung und prävention von brustkrebs
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties